Latest Earnings Results: Q3 '26
Estimated EPS
$2.23
Reported EPS
$2.65
Surprise
+19.04%
Estimated Rev
$649.94M
Reported Rev
$656.4M
Surprise
+0.99%
• Reported GAAP EPS of $2.65 up 17.26% YoY • Reported revenue of $656.4M up 0.52% YoY • Bio-Rad expects July 2026 restructuring pre-tax costs of approximately $80M to $90M and annual operating expense reductions of $30M to $35M by the end of 2027.
Bullish Takeaway
Bio-Rad's Clinical Diagnostics sales increased on quality systems and diabetes products; its restructuring plan targets $30M to $35M annual expense reductions, and $1.66B in cash, equivalents and short-term investments supports debt repayment.
Bearish Takeaway
Bio-Rad's Q3 gross margin declined from 52.6% to 50.1% with higher restructuring costs; Life Science sales decreased amid process chromatography and academic research challenges, while Middle East disruptions are expected to continue affecting EMEA.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $2.83 | -- | -- | N/A |
Q3 '26 | $2.23 | $2.65 | 19.04% | BEAT |
Q2 '26 | $1.75 | $2.62 | 49.92% | BEAT |
Q1 '26 | $1.97 | $1.89 | -4.21% | MISSED |
Q4 '25 | $2.71 | $2.51 | -7.31% | MISSED |